254882-14-9 Usage
General Description
The chemical compound (2S,4S)-1-tert-butyl 2-methyl-4-hydroxypiperidine-1,2-dicarboxylate, also known as tadalafil, is a medication primarily used to treat erectile dysfunction and benign prostatic hyperplasia. It belongs to the class of drugs known as phosphodiesterase type 5 inhibitors, which work by increasing blood flow to the penis during sexual stimulation, resulting in improved erectile function. Tadalafil is also used off-label for the treatment of pulmonary arterial hypertension. It is typically administered orally in the form of tablets, with a recommended dosage of 10 mg to 20 mg taken as needed prior to sexual activity. Side effects may include headache, indigestion, back pain, muscle aches, flushing, and nasal congestion. Tadalafil is available under the brand name Cialis, and it is important to consult a healthcare professional before use to ensure safety and efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 254882-14-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,4,8,8 and 2 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 254882-14:
(8*2)+(7*5)+(6*4)+(5*8)+(4*8)+(3*2)+(2*1)+(1*4)=159
159 % 10 = 9
So 254882-14-9 is a valid CAS Registry Number.
InChI:InChI=1/C12H21NO5/c1-12(2,3)18-11(16)13-6-5-8(14)7-9(13)10(15)17-4/h8-9,14H,5-7H2,1-4H3/t8-,9-/m0/s1
254882-14-9Relevant articles and documents
QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
-
Page/Page column 79-82, (2008/06/13)
The invention concerns quinazoline derivatives of the Formula (I), or pharmaceutically acceptable salts thereof: I wherein each of R1, R2, R3, R4 and m are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.
